Frontier Capital Management Co. LLC decreased its position in shares of Edwards Lifesciences Corp (NYSE:EW) by 4.1% in the 4th quarter, HoldingsChannel reports. The fund owned 770,058 shares of the medical research company’s stock after selling 32,563 shares during the period. Frontier Capital Management Co. LLC’s holdings in Edwards Lifesciences were worth $86,793,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Koch Industries Inc. grew its holdings in Edwards Lifesciences by 28,363.1% during the second quarter. Koch Industries Inc. now owns 1,397,254 shares of the medical research company’s stock worth $1,386,000 after buying an additional 1,392,345 shares in the last quarter. Atlantic Trust Group LLC grew its holdings in Edwards Lifesciences by 734.7% during the third quarter. Atlantic Trust Group LLC now owns 914,989 shares of the medical research company’s stock worth $100,018,000 after buying an additional 805,370 shares in the last quarter. Janus Henderson Group PLC grew its holdings in Edwards Lifesciences by 1,135.0% during the third quarter. Janus Henderson Group PLC now owns 619,703 shares of the medical research company’s stock worth $67,739,000 after buying an additional 569,525 shares in the last quarter. Old Mutual Global Investors UK Ltd. grew its holdings in Edwards Lifesciences by 83.0% during the third quarter. Old Mutual Global Investors UK Ltd. now owns 1,100,885 shares of the medical research company’s stock worth $120,337,000 after buying an additional 499,436 shares in the last quarter. Finally, Wells Fargo & Company MN grew its holdings in Edwards Lifesciences by 20.2% during the third quarter. Wells Fargo & Company MN now owns 2,548,282 shares of the medical research company’s stock worth $278,553,000 after buying an additional 429,022 shares in the last quarter. Hedge funds and other institutional investors own 81.61% of the company’s stock.

In other news, CEO Michael A. Mussallem sold 32,900 shares of the company’s stock in a transaction on Monday, October 30th. The stock was sold at an average price of $100.93, for a total transaction of $3,320,597.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Larry L. Wood sold 6,300 shares of the company’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $121.00, for a total value of $762,300.00. Following the transaction, the vice president now directly owns 116,148 shares in the company, valued at approximately $14,053,908. The disclosure for this sale can be found here. Insiders have sold a total of 197,820 shares of company stock worth $21,760,908 in the last ninety days. Insiders own 2.13% of the company’s stock.

Edwards Lifesciences Corp (NYSE:EW) opened at $121.72 on Friday. Edwards Lifesciences Corp has a 1 year low of $86.55 and a 1 year high of $122.93. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.76 and a current ratio of 3.49. The company has a market capitalization of $25,498.08, a price-to-earnings ratio of 35.38, a PEG ratio of 1.93 and a beta of 0.51.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, October 24th. The medical research company reported $0.84 EPS for the quarter, missing analysts’ consensus estimates of $0.86 by ($0.02). Edwards Lifesciences had a net margin of 22.47% and a return on equity of 27.22%. The firm had revenue of $821.50 million for the quarter, compared to analysts’ expectations of $833.85 million. During the same period in the prior year, the company earned $0.68 EPS. The firm’s quarterly revenue was up 11.1% on a year-over-year basis. sell-side analysts forecast that Edwards Lifesciences Corp will post 3.76 earnings per share for the current fiscal year.

Edwards Lifesciences declared that its Board of Directors has approved a share repurchase plan on Thursday, December 7th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire shares of its stock through open market purchases. Shares buyback plans are often a sign that the company’s board of directors believes its shares are undervalued.

Several equities research analysts recently issued reports on EW shares. JPMorgan Chase & Co. downgraded Edwards Lifesciences from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 2nd. Cowen set a $135.00 price target on Edwards Lifesciences and gave the stock a “buy” rating in a report on Sunday, December 10th. SunTrust Banks set a $124.00 price target on Edwards Lifesciences and gave the stock a “buy” rating in a report on Wednesday, October 25th. Barclays upgraded Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $125.00 to $135.00 in a report on Thursday, January 4th. Finally, Morgan Stanley decreased their price target on Edwards Lifesciences from $133.00 to $120.00 and set an “overweight” rating for the company in a report on Thursday, October 26th. Six equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Edwards Lifesciences has an average rating of “Buy” and an average target price of $129.57.

ILLEGAL ACTIVITY NOTICE: “Frontier Capital Management Co. LLC Sells 32,563 Shares of Edwards Lifesciences Corp (EW)” was first published by Daily Political and is owned by of Daily Political. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dailypolitical.com/2018/01/19/frontier-capital-management-co-llc-sells-32563-shares-of-edwards-lifesciences-corp-ew.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.